The Apothecary Shops Reaches Agreement with Pfizer to Distribute Inlyta™ - Sacramento Bee PDF Print
Sacramento Bee
On January 27, 2012, Inlyta™ (axitinib) was approved by the Food and Drug Administration for the treatment of advanced renal cell carcinoma (RCC) after failure of one systemic therapy, and throughout its development was recognized as one of Pfizer's

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.